The address, scheduled for 4:45 PM PT in Theater 1 at the San Diego Convention Center, will detail the company's recent corporate milestones and clinical development strategy. Whitfill is expected to leverage the global industry gathering to conduct one-on-one meetings with potential partners and investors.

Beyond the primary clinical focus, the company is expanding its reach into the cosmetic sector using proprietary filaggrin technologies. This initiative marks a strategic shift for the Branford-based firm, which currently maintains a diverse portfolio including the ATR-12 program for Netherton syndrome and the ATR-04 program targeting EGFR inhibitor-associated rashes. Azitra’s research platform, supported by machine learning and a library of approximately 1,500 bacterial strains, remains the core driver of these ongoing development efforts.